9606 — Duality Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- HK$27.60bn
- HK$23.63bn
- CNY1.94bn
Annual income statement for Duality Biotherapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 1,787 | 1,941 |
| Cost of Revenue | ||
| Gross Profit | 1,359 | 785 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 1,005 | 2,130 |
| Operating Profit | 781 | -189 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -202 | -1,015 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -358 | -1,050 |
| Net Income Before Extraordinary Items | ||
| Net Income | -358 | -1,050 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -358 | -1,050 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -4.3 | -12.3 |